fda pulls semaglutide Wegovy Pill Wins Approval as First GLP-1 Oral Treatment for Obesity and Weight Loss July 29, 2024: FDA issued

By potentially restoring gut integrity and reducing the source of systemic inflammation, BPC 157 could theoretically cut off the fuel supply for inflammatory acne at its root

Complement receptor 3 mediates NADPH oxidase activation and dopaminergic neurodegeneration through a Src-Erk-dependent pathway

A 2-fold reduction in M6A content was found in cells overexpressing miR-4443, whereas the expression of FSP1 was upregulated

Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a 41% lower risk of developing obesity-associated cancers in the short term for obese, nondiabetic patients, according to findings from an observational study published in Annals of Oncology